Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Found this on yahoo . This poster has intimate kno

Message Board Public Reply | Private Reply | Keep | Replies (5)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155188
(Total Views: 839)
Posted On: 07/16/2020 11:50:49 PM
Posted By: reallypeople?
Found this on yahoo . This poster has intimate knowledge of the fda process . Jean is the poster


Let's deconstruct the call a little. Be Bullish my friends. Been doing regulatory affairs for more than 2 decades. On the manufacture issue, this happens a lot. Critical to remember that the review did not question any stability issues, product quality, etc. The Manufacture had to do with co-packaged syryinges and needles. One way around this is to drop any copackaged syringe/needle from approval package, let docs use their own. This means CYDY will ahve just the vial. So this is easily correctable. No absolute need to have a "kit" of the vial + syringes. Also, every needle/syringe is FDA approved under the Med Device category Class II. So this is pretty easy. Appears that CYDY didn't put the details in the package. Easily correctable because every med device company will provide the data and/or provide a Right of Reference authorization letter.

On the clinical side: FDA did NOT ask for new trial; new methodology; new anything. Rather only asked for the updated data in ongoing trials. Important to remember that the actual Trials are now done as of June 2020. Now every patient in a "follow up" trial. that is, the trials are completed and need not be done again. Aggregating data is a common thing. If FDA knows about ongoing trials, they ask for the ongoing data. Happens all the time.
No clinical issues with methodology, patient enrollment numbers, lack of suitability controls; no questions on validation assays; data tables provided as being questionable or lacking credibility. In other words, CLINICALS LOOKS GOOD.


(15)
(1)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us